WO2005056003A1 - Dpp-iv inhibitors - Google Patents
Dpp-iv inhibitors Download PDFInfo
- Publication number
- WO2005056003A1 WO2005056003A1 PCT/EP2004/014040 EP2004014040W WO2005056003A1 WO 2005056003 A1 WO2005056003 A1 WO 2005056003A1 EP 2004014040 W EP2004014040 W EP 2004014040W WO 2005056003 A1 WO2005056003 A1 WO 2005056003A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- optionally substituted
- group
- compound according
- phenyl
- Prior art date
Links
- 0 *c1cccc(C[C@](CC(N2[C@@](CNS(C3CC3)(=O)=O)CCC2)=O)N)c1 Chemical compound *c1cccc(C[C@](CC(N2[C@@](CNS(C3CC3)(=O)=O)CCC2)=O)N)c1 0.000 description 6
- GLRBEYSMWYCASZ-UHFFFAOYSA-N C(C1NCCC1)Nc1nc(-c2ccccc2)n[o]1 Chemical compound C(C1NCCC1)Nc1nc(-c2ccccc2)n[o]1 GLRBEYSMWYCASZ-UHFFFAOYSA-N 0.000 description 1
- RIRXNAMRQITAMQ-UHFFFAOYSA-N CC(C)(C)OC(N1C(CNc2nc(-c3ccccc3)n[o]2)CCC1)=O Chemical compound CC(C)(C)OC(N1C(CNc2nc(-c3ccccc3)n[o]2)CCC1)=O RIRXNAMRQITAMQ-UHFFFAOYSA-N 0.000 description 1
- RPCJUCPTDVKOGT-UHFFFAOYSA-N CC(C)(C)OC(N1C(CNc2nc(-c3ncccc3)n[o]2)CCC1)=O Chemical compound CC(C)(C)OC(N1C(CNc2nc(-c3ncccc3)n[o]2)CCC1)=O RPCJUCPTDVKOGT-UHFFFAOYSA-N 0.000 description 1
- XSJPKMUFBHSIRA-UHFFFAOYSA-N CC(C)(C)OC(N1CC(CN)C1)=O Chemical compound CC(C)(C)OC(N1CC(CN)C1)=O XSJPKMUFBHSIRA-UHFFFAOYSA-N 0.000 description 1
- YEEGEOMIWYMLIL-UHFFFAOYSA-N CC(C)(C)OC(N1CC(COc2ccccc2)C1)=O Chemical compound CC(C)(C)OC(N1CC(COc2ccccc2)C1)=O YEEGEOMIWYMLIL-UHFFFAOYSA-N 0.000 description 1
- HOAPSBSHZCMNKQ-UHFFFAOYSA-O CN(CC(CCC1)[NH+]1C(CC(Cc1cc(Cl)ccc1)N)=O)S(C1CC1)(=O)=O Chemical compound CN(CC(CCC1)[NH+]1C(CC(Cc1cc(Cl)ccc1)N)=O)S(C1CC1)(=O)=O HOAPSBSHZCMNKQ-UHFFFAOYSA-O 0.000 description 1
- GOWADPNMGMEPQF-NEPJUHHUSA-N CS(NC[C@H](CCC1)N1C(C[C@@H](Cc(cc(c(F)c1)F)c1F)N)=O)(=O)=O Chemical compound CS(NC[C@H](CCC1)N1C(C[C@@H](Cc(cc(c(F)c1)F)c1F)N)=O)(=O)=O GOWADPNMGMEPQF-NEPJUHHUSA-N 0.000 description 1
- OLBSJIRHRCMCEF-BLIXFSHQSA-N C[C@H]([C@H](CCC1)N1C(C[C@@H](Cc(cccc1)c1F)N)=O)NS(c1ccccc1)(=O)=O Chemical compound C[C@H]([C@H](CCC1)N1C(C[C@@H](Cc(cccc1)c1F)N)=O)NS(c1ccccc1)(=O)=O OLBSJIRHRCMCEF-BLIXFSHQSA-N 0.000 description 1
- JYAGBFBAETXRJI-UUSAFJCLSA-N N[C@@H](CC(N1CC(CNC(c2ccccc2)=O)CCC1)=O)Cc(cccc1)c1F Chemical compound N[C@@H](CC(N1CC(CNC(c2ccccc2)=O)CCC1)=O)Cc(cccc1)c1F JYAGBFBAETXRJI-UUSAFJCLSA-N 0.000 description 1
- VZQBKLKLZZDXET-WHCXFUJUSA-N N[C@@H](CC(N1CC(CNS(c2ccccc2)(=O)=O)CCC1)=O)Cc(cccc1)c1F Chemical compound N[C@@H](CC(N1CC(CNS(c2ccccc2)(=O)=O)CCC1)=O)Cc(cccc1)c1F VZQBKLKLZZDXET-WHCXFUJUSA-N 0.000 description 1
- ANQHSFFUNMTTRS-MOPGFXCFSA-N N[C@@H](CC(N1[C@H](CNC(c2ccccc2)=O)CCC1)=O)Cc(cccc1)c1F Chemical compound N[C@@H](CC(N1[C@H](CNC(c2ccccc2)=O)CCC1)=O)Cc(cccc1)c1F ANQHSFFUNMTTRS-MOPGFXCFSA-N 0.000 description 1
- GGUFZJIZPROIJW-MNOVXSKESA-N N[C@@H](CC(N1[C@H](CNS(C(F)(F)F)(=O)=O)CCC1)=O)Cc(cc(c(F)c1)F)c1F Chemical compound N[C@@H](CC(N1[C@H](CNS(C(F)(F)F)(=O)=O)CCC1)=O)Cc(cc(c(F)c1)F)c1F GGUFZJIZPROIJW-MNOVXSKESA-N 0.000 description 1
- LSTBCAMTBZQTCR-OLZOCXBDSA-N N[C@@H](CC(N1[C@H](CNS(C2CC2)(=O)=O)CCC1)=O)Cc(cc(c(F)c1)F)c1F Chemical compound N[C@@H](CC(N1[C@H](CNS(C2CC2)(=O)=O)CCC1)=O)Cc(cc(c(F)c1)F)c1F LSTBCAMTBZQTCR-OLZOCXBDSA-N 0.000 description 1
- XDTTYXBUOAVNRJ-NEPJUHHUSA-N N[C@@H](CC(N1[C@H](CNS(CC(F)(F)F)(=O)=O)CCC1)=O)Cc(cc(c(F)c1)F)c1F Chemical compound N[C@@H](CC(N1[C@H](CNS(CC(F)(F)F)(=O)=O)CCC1)=O)Cc(cc(c(F)c1)F)c1F XDTTYXBUOAVNRJ-NEPJUHHUSA-N 0.000 description 1
- GUKXSTARZIHVLU-SJORKVTESA-N N[C@@H](CC(N1[C@H](CNS(c(cc(cc2)Cl)c2Cl)(=O)=O)CCC1)=O)Cc1ccccc1F Chemical compound N[C@@H](CC(N1[C@H](CNS(c(cc(cc2)Cl)c2Cl)(=O)=O)CCC1)=O)Cc1ccccc1F GUKXSTARZIHVLU-SJORKVTESA-N 0.000 description 1
- YRKHOTYVDVUVDA-SJORKVTESA-N N[C@@H](CC(N1[C@H](CNS(c(cccc2)c2F)(=O)=O)CCC1)=O)Cc(cccc1)c1F Chemical compound N[C@@H](CC(N1[C@H](CNS(c(cccc2)c2F)(=O)=O)CCC1)=O)Cc(cccc1)c1F YRKHOTYVDVUVDA-SJORKVTESA-N 0.000 description 1
- CIYSGOBBUFBQIH-MOPGFXCFSA-N N[C@@H](CC(N1[C@H](CNS(c2ccccc2)(=O)=O)CCC1)=O)Cc1cc(Cl)ccc1 Chemical compound N[C@@H](CC(N1[C@H](CNS(c2ccccc2)(=O)=O)CCC1)=O)Cc1cc(Cl)ccc1 CIYSGOBBUFBQIH-MOPGFXCFSA-N 0.000 description 1
- VFFBZRIOQCTHJG-MOPGFXCFSA-N N[C@@H](CC(N1[C@H](CNS(c2ccccc2)(=O)=O)CCCC1)=O)Cc1ccccc1F Chemical compound N[C@@H](CC(N1[C@H](CNS(c2ccccc2)(=O)=O)CCCC1)=O)Cc1ccccc1F VFFBZRIOQCTHJG-MOPGFXCFSA-N 0.000 description 1
- YJKFKJDPCJBSJP-MSOLQXFVSA-N N[C@@H](CC(N1[C@H](CNc(nc2)ccc2C#N)CCC1)=O)Cc(cccc1)c1F Chemical compound N[C@@H](CC(N1[C@H](CNc(nc2)ccc2C#N)CCC1)=O)Cc(cccc1)c1F YJKFKJDPCJBSJP-MSOLQXFVSA-N 0.000 description 1
- VNKLHOHFAWRPIT-CVEARBPZSA-N N[C@@H](CC(N1[C@H](CNc2cnccn2)CCC1)=O)Cc(cccc1)c1F Chemical compound N[C@@H](CC(N1[C@H](CNc2cnccn2)CCC1)=O)Cc(cccc1)c1F VNKLHOHFAWRPIT-CVEARBPZSA-N 0.000 description 1
- SMOZREHTDSXFDU-CPSIJMPNSA-N N[C@@H](CC(N1[C@H](COC(C2)=CC=CC2F)CCC1)=O)Cc1cccc(Cl)c1 Chemical compound N[C@@H](CC(N1[C@H](COC(C2)=CC=CC2F)CCC1)=O)Cc1cccc(Cl)c1 SMOZREHTDSXFDU-CPSIJMPNSA-N 0.000 description 1
- CTPYPSLBYQWSTO-CABCVRRESA-N N[C@@H](CC(N1[C@H](COCC2CC2)CCC1)=O)Cc(c(F)c1)cc(F)c1F Chemical compound N[C@@H](CC(N1[C@H](COCC2CC2)CCC1)=O)Cc(c(F)c1)cc(F)c1F CTPYPSLBYQWSTO-CABCVRRESA-N 0.000 description 1
- HPQPUHIZEGPIRT-MOPGFXCFSA-N N[C@@H](CC(N1[C@H](COc(cc2)ccc2C#N)CCC1)=O)Cc1ccccc1F Chemical compound N[C@@H](CC(N1[C@H](COc(cc2)ccc2C#N)CCC1)=O)Cc1ccccc1F HPQPUHIZEGPIRT-MOPGFXCFSA-N 0.000 description 1
- BHRMMYVOEWKURV-MSOLQXFVSA-N N[C@@H](CC(N1[C@H](COc2cc(F)ccc2)CCC1)=O)Cc1ccccc1F Chemical compound N[C@@H](CC(N1[C@H](COc2cc(F)ccc2)CCC1)=O)Cc1ccccc1F BHRMMYVOEWKURV-MSOLQXFVSA-N 0.000 description 1
- YLNNGMZPGMFNOR-MSOLQXFVSA-N N[C@@H](CC(N1[C@H](COc2ccccc2)CCC1)=O)Cc1ccccc1F Chemical compound N[C@@H](CC(N1[C@H](COc2ccccc2)CCC1)=O)Cc1ccccc1F YLNNGMZPGMFNOR-MSOLQXFVSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- VGJWVEYTYIBXIA-UHFFFAOYSA-N OC(C(F)(F)F)O Chemical compound OC(C(F)(F)F)O VGJWVEYTYIBXIA-UHFFFAOYSA-N 0.000 description 1
- BURMOJKVPYIKIF-UHFFFAOYSA-N OC(C(F)(F)[F]C1NCC1COc1ccccc1)=O Chemical compound OC(C(F)(F)[F]C1NCC1COc1ccccc1)=O BURMOJKVPYIKIF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL04803694T PL1613304T3 (en) | 2003-12-09 | 2004-12-09 | Dpp-iv inhibitors |
JP2006543480A JP2007513910A (en) | 2003-12-09 | 2004-12-09 | DPP-IV inhibitor |
SI200430469T SI1613304T1 (en) | 2003-12-09 | 2004-12-09 | Dpp-iv inhibitors |
BRPI0417458-5A BRPI0417458A (en) | 2003-12-09 | 2004-12-09 | dpp-iv inhibitor compounds, pharmaceutically acceptable salts and prodrugs thereof, their preparation processes, pharmaceutical composition comprising them and use of said compounds in the manufacture of medicaments |
DK04803694T DK1613304T3 (en) | 2003-12-09 | 2004-12-09 | DPP-IV inhibitors |
EP04803694A EP1613304B1 (en) | 2003-12-09 | 2004-12-09 | Dpp-iv inhibitors |
US10/582,054 US20080027035A1 (en) | 2003-12-09 | 2004-12-09 | Dpp-Iv Inhibitors |
AU2004296553A AU2004296553B2 (en) | 2003-12-09 | 2004-12-09 | DPP-IV inhibitors |
MXPA06006652A MXPA06006652A (en) | 2003-12-09 | 2004-12-09 | Dpp-iv inhibitors. |
CA002548742A CA2548742A1 (en) | 2003-12-09 | 2004-12-09 | Dpp-iv inhibitors |
DE602004008895T DE602004008895T2 (en) | 2003-12-09 | 2004-12-09 | DPP-IV-HEMMER |
IL176062A IL176062A0 (en) | 2003-12-09 | 2006-05-31 | Dpp-iv inhibitors |
NO20062644A NO20062644L (en) | 2003-12-09 | 2006-06-08 | DPP-IV inhibitors |
HK06107175A HK1087022A1 (en) | 2003-12-09 | 2006-06-24 | Dpp-iv inhibitors |
HR20070560T HRP20070560T3 (en) | 2003-12-09 | 2007-12-12 | Dpp-iv inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03028211A EP1541143A1 (en) | 2003-12-09 | 2003-12-09 | Dpp-iv inhibitors |
EP03028211.5 | 2003-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005056003A1 true WO2005056003A1 (en) | 2005-06-23 |
Family
ID=34486147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/014040 WO2005056003A1 (en) | 2003-12-09 | 2004-12-09 | Dpp-iv inhibitors |
Country Status (24)
Country | Link |
---|---|
US (1) | US20080027035A1 (en) |
EP (2) | EP1541143A1 (en) |
JP (1) | JP2007513910A (en) |
KR (1) | KR100845397B1 (en) |
CN (1) | CN1905868A (en) |
AT (1) | ATE372767T1 (en) |
AU (1) | AU2004296553B2 (en) |
BR (1) | BRPI0417458A (en) |
CA (1) | CA2548742A1 (en) |
CY (1) | CY1106969T1 (en) |
DE (1) | DE602004008895T2 (en) |
DK (1) | DK1613304T3 (en) |
ES (1) | ES2291966T3 (en) |
HK (1) | HK1087022A1 (en) |
HR (1) | HRP20070560T3 (en) |
IL (1) | IL176062A0 (en) |
MX (1) | MXPA06006652A (en) |
NO (1) | NO20062644L (en) |
PL (1) | PL1613304T3 (en) |
PT (1) | PT1613304E (en) |
RU (1) | RU2006119302A (en) |
SI (1) | SI1613304T1 (en) |
WO (1) | WO2005056003A1 (en) |
ZA (1) | ZA200604719B (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007053819A2 (en) | 2005-10-31 | 2007-05-10 | Bristol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
WO2007072083A1 (en) | 2005-12-23 | 2007-06-28 | Prosidion Limited | Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione |
WO2007077508A2 (en) | 2005-12-30 | 2007-07-12 | Ranbaxy Laboratories Limited | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
US7259160B2 (en) | 2003-07-31 | 2007-08-21 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US7265128B2 (en) | 2003-01-17 | 2007-09-04 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7332520B2 (en) | 2003-06-06 | 2008-02-19 | Merck & Co., Inc. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2008028662A1 (en) * | 2006-09-07 | 2008-03-13 | Santhera Pharmaceuticals (Schweiz) Ag | N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus |
EP1905759A1 (en) * | 2006-09-07 | 2008-04-02 | Santhera Pharmaceuticals (Schweiz) AG | N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment oftype 2 diabetes mellitus |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
US7388019B2 (en) | 2003-01-31 | 2008-06-17 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2008093960A1 (en) * | 2007-01-30 | 2008-08-07 | Lg Life Sciences, Ltd. | Novel dipeptidyl peptidase-iv inhibitors |
WO2008130151A1 (en) * | 2007-04-19 | 2008-10-30 | Dong-A Pharm. Co., Ltd. | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity |
US7456204B2 (en) | 2003-06-17 | 2008-11-25 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2009003681A1 (en) * | 2007-07-02 | 2009-01-08 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
EP2019099A1 (en) * | 2007-07-02 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Dpp-IV inhibitors |
US7560455B2 (en) | 2003-05-14 | 2009-07-14 | Merck & Co., Inc. | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7671073B2 (en) | 2004-05-18 | 2010-03-02 | Merck Sharp & Dohme Corp. | Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US7687492B2 (en) | 2004-05-04 | 2010-03-30 | Merck Sharp & Dohme Corp. | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US7728146B2 (en) | 2006-04-12 | 2010-06-01 | Probiodrug Ag | Enzyme inhibitors |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
CN101823987B (en) * | 2009-03-06 | 2014-06-04 | 中国科学院上海药物研究所 | New DPP-IV inhibitors and preparation method and application thereof |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2450722A1 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2006098342A1 (en) * | 2005-03-16 | 2006-09-21 | Astellas Pharma Inc. | Piperazinyl compounds |
US7860904B2 (en) * | 2007-04-24 | 2010-12-28 | Microsoft Corporation | Standalone execution of incomplete data flows |
CN102838589B (en) * | 2008-09-23 | 2014-03-26 | 成都地奥制药集团有限公司 | Method for preparing N substituted pyrrolidine derivative through acylation of methyl sulfone chloride |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
BR112013019683B1 (en) | 2011-02-07 | 2022-04-19 | Biogen Inc | Compounds that modulate s1p, pharmaceutical composition, and use thereof |
US20160350201A1 (en) * | 2015-05-27 | 2016-12-01 | International Business Machines Corporation | Etl data flow design assistance through progressive context matching |
EP3316877B1 (en) | 2015-07-02 | 2019-10-30 | Horizon Orphan LLC | Ado-resistant cysteamine analogs and uses thereof |
CN105362268A (en) * | 2015-12-15 | 2016-03-02 | 上海壹志医药科技有限公司 | Pharmaceutical application of demethyleneberberine |
CN106526047A (en) * | 2016-11-15 | 2017-03-22 | 迪沙药业集团有限公司 | Determination method of R-succinic acid trelagliptin optical purity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083128A1 (en) * | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
WO2003000180A2 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003000181A2 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10340800A1 (en) * | 2002-12-20 | 2004-07-01 | Merck Patent Gmbh | Production of acrylic bone cement, e.g. for anchoring prostheses in bone, involves using X-ray contrast medium which has been functionalised with (meth)acrylate after coating with melamine-formaldehyde resin |
-
2003
- 2003-12-09 EP EP03028211A patent/EP1541143A1/en not_active Withdrawn
-
2004
- 2004-12-09 DK DK04803694T patent/DK1613304T3/en active
- 2004-12-09 PT PT04803694T patent/PT1613304E/en unknown
- 2004-12-09 MX MXPA06006652A patent/MXPA06006652A/en not_active Application Discontinuation
- 2004-12-09 CA CA002548742A patent/CA2548742A1/en not_active Abandoned
- 2004-12-09 PL PL04803694T patent/PL1613304T3/en unknown
- 2004-12-09 WO PCT/EP2004/014040 patent/WO2005056003A1/en active Application Filing
- 2004-12-09 KR KR1020067013752A patent/KR100845397B1/en not_active IP Right Cessation
- 2004-12-09 AT AT04803694T patent/ATE372767T1/en not_active IP Right Cessation
- 2004-12-09 DE DE602004008895T patent/DE602004008895T2/en not_active Expired - Fee Related
- 2004-12-09 AU AU2004296553A patent/AU2004296553B2/en not_active Ceased
- 2004-12-09 RU RU2006119302/04A patent/RU2006119302A/en not_active Application Discontinuation
- 2004-12-09 JP JP2006543480A patent/JP2007513910A/en not_active Withdrawn
- 2004-12-09 EP EP04803694A patent/EP1613304B1/en active Active
- 2004-12-09 US US10/582,054 patent/US20080027035A1/en not_active Abandoned
- 2004-12-09 CN CNA2004800404476A patent/CN1905868A/en active Pending
- 2004-12-09 SI SI200430469T patent/SI1613304T1/en unknown
- 2004-12-09 BR BRPI0417458-5A patent/BRPI0417458A/en not_active IP Right Cessation
- 2004-12-09 ES ES04803694T patent/ES2291966T3/en active Active
-
2006
- 2006-05-31 IL IL176062A patent/IL176062A0/en unknown
- 2006-06-08 NO NO20062644A patent/NO20062644L/en not_active Application Discontinuation
- 2006-06-08 ZA ZA200604719A patent/ZA200604719B/en unknown
- 2006-06-24 HK HK06107175A patent/HK1087022A1/en not_active IP Right Cessation
-
2007
- 2007-10-30 CY CY20071101404T patent/CY1106969T1/en unknown
- 2007-12-12 HR HR20070560T patent/HRP20070560T3/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083128A1 (en) * | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
WO2003000180A2 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003000181A2 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7265128B2 (en) | 2003-01-17 | 2007-09-04 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7388019B2 (en) | 2003-01-31 | 2008-06-17 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7560455B2 (en) | 2003-05-14 | 2009-07-14 | Merck & Co., Inc. | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7332520B2 (en) | 2003-06-06 | 2008-02-19 | Merck & Co., Inc. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7456204B2 (en) | 2003-06-17 | 2008-11-25 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7259160B2 (en) | 2003-07-31 | 2007-08-21 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US7687492B2 (en) | 2004-05-04 | 2010-03-30 | Merck Sharp & Dohme Corp. | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US7671073B2 (en) | 2004-05-18 | 2010-03-02 | Merck Sharp & Dohme Corp. | Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
WO2007053819A2 (en) | 2005-10-31 | 2007-05-10 | Bristol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
EP2487154A1 (en) * | 2005-10-31 | 2012-08-15 | Bristol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods |
WO2007053819A3 (en) * | 2005-10-31 | 2008-03-13 | Bristol Myers Squibb Co | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
US7488725B2 (en) | 2005-10-31 | 2009-02-10 | Bristol-Myers Squibb Co. | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods |
WO2007072083A1 (en) | 2005-12-23 | 2007-06-28 | Prosidion Limited | Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione |
WO2007077508A2 (en) | 2005-12-30 | 2007-07-12 | Ranbaxy Laboratories Limited | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
WO2007077508A3 (en) * | 2005-12-30 | 2007-10-25 | Ranbaxy Lab Ltd | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
US7728146B2 (en) | 2006-04-12 | 2010-06-01 | Probiodrug Ag | Enzyme inhibitors |
EP1905759A1 (en) * | 2006-09-07 | 2008-04-02 | Santhera Pharmaceuticals (Schweiz) AG | N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment oftype 2 diabetes mellitus |
WO2008028662A1 (en) * | 2006-09-07 | 2008-03-13 | Santhera Pharmaceuticals (Schweiz) Ag | N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008093960A1 (en) * | 2007-01-30 | 2008-08-07 | Lg Life Sciences, Ltd. | Novel dipeptidyl peptidase-iv inhibitors |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
WO2008130151A1 (en) * | 2007-04-19 | 2008-10-30 | Dong-A Pharm. Co., Ltd. | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity |
US8030315B2 (en) | 2007-04-19 | 2011-10-04 | Dong-A Pharm. Co., Ltd. | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity |
CN101663282B (en) * | 2007-04-19 | 2012-02-15 | 东亚制药株式会社 | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity |
JP2011500508A (en) * | 2007-04-19 | 2011-01-06 | ドン・ア・ファーム・カンパニー・リミテッド | DPP-IV inhibitor containing β-amino group, method for producing the same, and pharmaceutical composition for preventing and treating diabetes or obesity containing the same as an active ingredient |
AU2008241692B2 (en) * | 2007-04-19 | 2011-02-10 | Dong-A Pharm. Co., Ltd. | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity |
CN102516184B (en) * | 2007-04-19 | 2015-03-25 | 东亚St株式会社 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity |
CN102516184A (en) * | 2007-04-19 | 2012-06-27 | 东亚制药株式会社 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity |
EP2019099A1 (en) * | 2007-07-02 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Dpp-IV inhibitors |
WO2009003681A1 (en) * | 2007-07-02 | 2009-01-08 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
CN101823987B (en) * | 2009-03-06 | 2014-06-04 | 中国科学院上海药物研究所 | New DPP-IV inhibitors and preparation method and application thereof |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Also Published As
Publication number | Publication date |
---|---|
CN1905868A (en) | 2007-01-31 |
PT1613304E (en) | 2007-11-14 |
DE602004008895D1 (en) | 2007-10-25 |
BRPI0417458A (en) | 2007-03-13 |
AU2004296553B2 (en) | 2008-09-04 |
RU2006119302A (en) | 2008-01-20 |
NO20062644L (en) | 2006-09-07 |
HK1087022A1 (en) | 2006-10-06 |
SI1613304T1 (en) | 2007-12-31 |
DK1613304T3 (en) | 2008-01-21 |
CY1106969T1 (en) | 2012-09-26 |
HRP20070560T3 (en) | 2008-01-31 |
US20080027035A1 (en) | 2008-01-31 |
KR20060108756A (en) | 2006-10-18 |
ZA200604719B (en) | 2007-12-27 |
CA2548742A1 (en) | 2005-06-23 |
MXPA06006652A (en) | 2007-02-20 |
ES2291966T3 (en) | 2008-03-01 |
ATE372767T1 (en) | 2007-09-15 |
KR100845397B1 (en) | 2008-07-09 |
AU2004296553A1 (en) | 2005-06-23 |
EP1613304B1 (en) | 2007-09-12 |
EP1541143A1 (en) | 2005-06-15 |
DE602004008895T2 (en) | 2008-06-19 |
JP2007513910A (en) | 2007-05-31 |
EP1613304A1 (en) | 2006-01-11 |
IL176062A0 (en) | 2006-10-05 |
PL1613304T3 (en) | 2008-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1613304B1 (en) | Dpp-iv inhibitors | |
EP1702916A1 (en) | DPP-IV inhibitors | |
AU2005229330B2 (en) | DPP-IV inhibitors | |
EP1791536A1 (en) | 1-[(3r)-amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2r)-carboxylic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diabetes mellitus | |
US20080064728A1 (en) | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | |
EP1828138A1 (en) | Dpp-iv inhibitors | |
EP1604989A1 (en) | DPP-IV inhibitors | |
EP1791817A1 (en) | Dpp-iv inhibitors | |
EP1541148A1 (en) | Dpp-iv inhibitors | |
WO2009003681A1 (en) | Dpp-iv inhibitors | |
EP1905759A1 (en) | N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment oftype 2 diabetes mellitus | |
EP2019099A1 (en) | Dpp-IV inhibitors | |
KR20070030884A (en) | 1-[3r-amino-4-2-fluoro-phenyl-butyl]-pyrrolidine-2r-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase ivdpp-iv inhibitors for the treatment of type 2 diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004803694 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004803694 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 176062 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004296553 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/04719 Country of ref document: ZA Ref document number: 2548742 Country of ref document: CA Ref document number: 12006501128 Country of ref document: PH Ref document number: 200604719 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006543480 Country of ref document: JP Ref document number: PA/a/2006/006652 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2104/CHENP/2006 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004296553 Country of ref document: AU Date of ref document: 20041209 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004296553 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 548365 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067013752 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006119302 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480040447.6 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067013752 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0417458 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10582054 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004803694 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2007/0481 Country of ref document: RS |
|
WWP | Wipo information: published in national office |
Ref document number: 10582054 Country of ref document: US |